現在地

土岐 浩介(ドキ コウスケ; Doki, Kosuke)

研究者情報全体を表示

論文
  • Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
    Kousuke Doki; Yukio Sekiguchi; Keisuke Kuga; Kazutaka Aon...
    Drug Metabolism and Pharmacokinetics/30(4)/pp.257-262, 2015-08
  • 臨床試験のモニタリングと監査に関するガイドライン
    土岐 浩介
    臨床薬理 = JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS/46(3)/p.133, 2015-05
  • 治験モニターの治験実施医療機関への訪問実態 ―治験効率化に向けた一考察―
    飯村 美波; 土岐 浩介; 嶋田 沙織; 鶴嶋 英夫; 松村 明; 本間...
    臨床薬理 = JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS/46(2)/pp.71-75, 2015
  • Stereoselective analysis of flecainide enantiomers using reversed-phase liquid chromatography for assessing CYP2D6 activity
    Kousuke Doki; Sekiguchi Yukio; Kuga Keisuke; Aonuma Kazut...
    BIOMEDICAL CHROMATOGRAPHY/28(9)/pp.1193-1198, 2014-09
  • SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients
    Doki Kosuke
    Pharmacogenet Genomics/23(7)/pp.349-354, 2013
  • CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis
    Doki Kosuke
    Pharmacogenet Genomics/22(11)/pp.777-783, 2012
  • Open-well stability of reagent cartridge for affinity column-mediated immunoassay of blood tacrolimus concentration
    Doki Kosuke
    Clin Chim Acta/411(11-12)/pp.888-889, 2010
  • Difference in blood tacrolimus concentration between ACMIA and MEIA in samples with low haematocrit values
    Doki Kosuke
    J Pharm Pharmacol/62(9)/pp.1185-1188, 2010
  • 処方オーダーシステムと連動した麻薬管理システムの導入と評価
    土岐 浩介
    日本病院薬剤師会雑誌/45/pp.1099-1101, 2009
  • Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism
    Doki Kosuke; Homma Masato; Kuga Keisuke; Aonuma Kazutaka;...
    Br J Clin Pharmacol/68(1)/pp.89-96, 2009
  • 膠原病患者におけるグルココルチコイド製剤による副作用発現に関する実態調査
    Nakajima Aya; 土岐 浩介; Homma Masato; Sagae Terumi; Sait...
    Yakugaku Zasshi/129(4)/pp.445-450, 2009
  • Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
    Doki Kosuke
    Br J Clin Pharmacol/67(1)/pp.44-49, 2009
  • Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects
    Doki Kosuke
    Br J Clin Pharmacol/66(1)/pp.154-155, 2008
  • Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia
    Doki Kosuke
    Eur J Clin Pharmacology./63(10)/pp.951-957, 2007
  • Impact of serum flecainide level on control of atrial fibrillation in a case treated with cardiac resynchronization therapy
    Doki Kosuke
    J Clin Pharm Ther/32(4)/pp.409-411, 2007
  • Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
    Doki Kosuke
    Eur J Clin Pharmacol/62(11)/pp.919-926, 2006
  • Assessment of serum flecainide trough levels in patients with tachyarrhythmia
    Doki Kosuke
    J Pharm Pharmacol/57(1)/pp.47-51, 2005
  • Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography
    Doki Kosuke
    J Pharm Biomed Anal/35(5)/pp.1307-1312, 2004
  • Drug interaction of tizanidine and fluvoxamine
    Doki Kosuke
    Clin Pharmacol Ther/76(5), 2004
  • Effects of absorption rate on the pre-systemic chiral inversion of ibuprofen in rabbits
    Doki Kosuke
    J Pharm Pharmacol/55(8)/pp.1091-1097, 2003